OncoMatch/Lung Cancer — Non-Small Cell (NSCLC)/KRAS
Lung Cancer — Non-Small Cell (NSCLC)KRAS Clinical Trials
KRAS mutations are the most common oncogenic driver in NSCLC, found in 25–30% of cases; KRAS G12C accounts for approximately 13% of all NSCLC cases (roughly half of all KRAS-mutant NSCLC). Sotorasib and adagrasib are FDA-approved for KRAS G12C-mutant NSCLC after prior therapy. Trials explore G12C inhibitor combinations, novel inhibitors for other KRAS variants (G12D, G12V), and SOS1/MEK pathway co-targeting.
Top recruiting KRAS Lung Cancer — Non-Small Cell (NSCLC) trials
Ranked by phase and US site count.
See all trials matched to your profile →Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
Mirati Therapeutics Inc.
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Eli Lilly and Company
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
Eli Lilly and Company
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
Mirati Therapeutics Inc.
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
Revolution Medicines, Inc.
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
Hoffmann-La Roche
More KRAS Lung Cancer — Non-Small Cell (NSCLC) trials
See all in search →3 international trials (no US sites)
FDA-approved therapies for KRAS Lung Cancer — Non-Small Cell (NSCLC)
Approved agents for this molecular target. Indication labels specify the approved patient population — some approvals apply to specific variants only.